Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Sanofi to help second rival produce COVID-19 vaccines

French drug maker Sanofi is going to produce as many as 12 million coronavirus vaccine doses per month for rival Johnson & Johnson

Via AP news wire
Monday 22 February 2021 10:07 EST
Virus Outbreak France
Virus Outbreak France (Copyright 2019 The Associated Press. All rights reserved.)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

French drug maker Sanofi battling development delays with its own vaccine candidates against COVID-19, is turning over more of its vaccine production facilities to industrial competitors, teaming up with Johnson & Johnson to produce millions of doses of its rival coronavirus vaccine.

Johnson & Johnson is the second rival to have struck a deal with Sanofi to use its facilities, an unusual collaboration for the competitive industry now facing intense pressure from governments to speed up the production of vaccines against the devastating global pandemic.

Sanofi's CEO, Paul Hudson, said the agreement announced by the company on Monday demonstrates its “commitment to the collective effort to ending this crisis as quickly as possible.”

Sanofi is still prioritizing the development of its own two coronavirus vaccine programs, Hudson said in a company statement.

But “where we have the right manufacturing capabilities, we are stepping forward to show solidarity in the industry and continue doing our part in the fight against COVID-19,” he added.

Sanofi said its Marcy l’Etoile vaccine manufacturing plant near the city of Lyon will formulate and fill vials of the single-dose vaccine for Johnson & Johnson’s Janssen companies.

Sanofi will blend together vaccine ingredients sent to it by Janssen and fill vials, and then ship the full vials back to Janssen for packaging. The French plant is expected to produce about 12 million doses per month, starting in the second half of this year.

Sanofi had already previously announced that its facilities in Frankfurt, Germany, also will help bottle and package 125 million vaccine doses for the rival partnership of Pfizer-BioNTech.

Sanofi’s latest announcement was quickly trumpeted by French President Emmanuel Macron. His government has pressed Sanofi to use its facilities to help make vaccines from its rivals, because of the high global demand for vaccines and supply problems.

“We must together accelerate the production of vaccines with industrial partnerships,” Macron tweeted.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in